Owkin unveils new insights into the opportunities and challenges for digital pathology and AI solutions in healthcare

Owkin, the first end-to-end AI-biotech that uses cutting-edge AI to unlock precision drug discovery, development, and diagnostics, has launched its latest report, State of the Nation: Opportunities and Challenges for Digital Pathology and AI Solutions, exploring the evolving landscape of digital pathology and AI in healthcare across the United States, United Kingdom, and France.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212654982/en/

Conducted in partnership with Censuswide, the research highlights challenges that pathologists and oncologists face around increasing workloads, complexity of diagnoses, and burnout. It also underscores the potential of AI to enhance patient care, streamline workflows, and improve access to diagnostics amid the growing demand for personalized therapies for complex diseases like cancer.

Meriem Sefta, Chief Diagnostics Officer at Owkin, said: “When doctors are overworked, it can cause diagnostic errors, delays in reporting, and overall reductions in the quality of care. This can then negatively affect patient outcomes. Digital pathology and AI are poised to make a real difference in this context, relieving this burden on pathologists and ensuring patient care is always as effective as possible.”

Addressing burnout in the industry

The survey reveals a number of current pain points in the diagnostic process, including issues related to operations, workload, ways of working, burnout, and stress. The report revealed that 55%of pathologists and oncologists experience high stress or burnout, with 52% citing a heavy workload as a significant burden. Nearly half (40%) even rated their mental health as neutral to poor due to their jobs.

Rising cancer incidence and the increasing complexity of diagnoses exacerbate these pressures, with many pathologists nearing retirement and fewer entering the field. Burnout and mental health issues don’t just affect healthcare professionals – it has significant implications for patients, with 35% of responses indicating that the burdens they face are detrimental to patient care. Nearly 40% said they couldn’t get pathology test results quickly enough and could not see or help as many patients as they'd like.

By reducing testing times and facilitating precision medicine, AI and digital pathology can potentially improve access to care, especially in underserved regions. However, pathologists and oncologists stress that technological solutions must complement, not replace, human expertise.

AI’s transformative potential

Digital pathology, accompanied by AI solutions, has the potential to revolutionize the field and alleviate pressure on pathologists. By streamlining the testing process and automating routine tasks, labs can reduce waiting times, enable faster analysis and delivery of results, and resolve delays that often hinder patient care.

Encouragingly, 77% of surveyed professionals believe AI can cut test waiting times and address staffing challenges, while 74% see its potential to accelerate oncological diagnostics. Trust in AI is also growing, with 82% of pathologists expressing confidence in AI tools and 70% believing their patients are comfortable with its use.

AI-powered tools offer the potential to enhance biomarker screening, prioritize urgent cases, and provide new insights into patient outcomes and treatment responses, but survey respondents emphasized the need for clear clinical evidence and successful trials to drive adoption. Integration of AI tools is further slowed by barriers such as insufficient IT resources and infrastructure (43%), the cost of digitization and AI technology (23%), and lack of funding (23%) have slowed the adoption of digital pathology and AI solutions.

The future of pathology depends on embracing AI and digital technologies to enhance patient care and streamline workflows, as well as overcoming challenges around funding and implementation. The demand for accurate and timely pathology solutions is rapidly growing, and AI is poised to catalyze digital pathology adoption.

The way forward

Owkin is at the forefront of digital pathology innovation with solutions like MSIntuit CRC and TLS Detect. This report highlights key steps to advance digital pathology and AI adoption, including standardizing imaging protocols and workflows for interoperability, enhancing accessibility with cloud-based solutions, building trust through education on AI’s capabilities, and revising reimbursement models to incentivize innovation.

In a world increasingly dependent on technology to transform our ways of working, understanding how pathologists and oncologists can adopt AI products into their day-to-day work will be critical in generating more accurate insights that can enhance cancer diagnostic accuracy and ultimately lead to better patient outcomes.

On December 9th, Owkin hosted a webinar round table with expert panelists from UK, US, and France to dive into the context of the results from the survey report and unpack the state of play of digitization and integration of AI solutions into pathology workflows. A replay of the webinar and the full report can be found here.

About Owkin

Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across seven cancer indications. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.

About the research

The research, comprising 10 multiple-choice and open-answer questions, was conducted by Censuswide with 312 Pathologists & Oncologists across the United Kingdom, United States, and France in July 2024. Censuswide abide by and employ members of the Market Research Society which is based on the ESOMAR principles and are members of The British Polling Council.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212654982/en/